Activist Investor Legion Partners Nominates 7 Directors to Genesco Board (Reuters) BOSTON (Reuters) – Activist investor Legion Partners Asset Management...
Keep Reading →
April 12 - Hedge Funds, Insider Trading - Comments
Fund Administrator for Fortress, Pimco and Others Suffers Data Breach Through Vendor (The Wall Street Journal) A ransomware attack against a vendor of...
Keep Reading →
July 27 - Hedge Funds, Insider Trading - Comments
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has resolved to dispose of its cancer drugs unit to Ipsen. Some of these drugs include Doxil and Onivyde....
Keep Reading →
January 10 - News, Stock Analysis - Comments
Insider Monkey keeps a keen eye on the activity of the top hedge funds in the world, as our research has shown that hedge funds’ long positions can...
Keep Reading →
November 26 - Hedge Funds, News - Comments
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) and Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) have moved closer to introducing their generic version...
Keep Reading →
November 1 - News - Comments
The markets have opened the fourth quarter on a negative note. While there are uncertainties on account of upcoming presidential election and deteriorating...
Keep Reading →
October 3 - Market Movers, News - Comments
After opening flat and falling into the red, the broader markets are now in the green this afternoon as investors weigh the overall positive start to...
Keep Reading →
April 14 - Market Movers, News - Comments
Tuesday was a bad day for three healthcare stocks in particular. Shares of Merrimack Pharmaceuticals Inc (NASDAQ:MACK), Inovio Pharmaceuticals Inc (NASDAQ...
Keep Reading →
September 29 - Hedge Funds, Market Movers, News - Comments
Should you buy Merrimack Pharmaceuticals Inc (NASDAQ:MACK) stock today? The firm’s share price surged 10.22% on June 18 to attain a closing price of...
Keep Reading →
June 19 - Hedge Funds, News - Comments
June 23, two Board Directors at Merrimack Pharmaceuticals Inc (NASDAQ:MACK), a $741 million market cap biotechnology company, spent a total of $467,787...
Keep Reading →
June 24 - Insider Trading, News - Comments
Should Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) investors track the following data? At the moment, there are plenty of metrics investors can use to...
Keep Reading →
September 17 - News - Comments
Is it smart to be bullish on EXACT Sciences Corporation (NASDAQ:EXAS)? In the financial world, there are a multitude of gauges shareholders can use to...
Keep Reading →
September 6 - News - Comments
Is it smart to be bullish on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)? In the eyes of many of your fellow readers, hedge funds are viewed as overrated...
Keep Reading →
September 5 - News - Comments
Is Halozyme Therapeutics, Inc. (NASDAQ:HALO) a good investment? Now, according to many investors, hedge funds are seen as delayed, outdated financial...
Keep Reading →
September 4 - News - Comments
Is Array Biopharma Inc (NASDAQ:ARRY) a good investment? At the moment, there are many methods investors can use to analyze Mr. Market. Some of the most...
Keep Reading →
August 30 - News - Comments
While the major indexes pulled back this week, their declines paled in comparison to the huge drops experienced by a handful of health-care stocks. Here...
Keep Reading →
August 19 - News - Comments
August might be hot for most of the country, but the first full week of the month wasn’t so hot for some stocks. Here are some of the most horrendous...
Keep Reading →
August 12 - News - Comments
A great week for the overall market didn’t trickle down to every stock. Here are three of the most horrendous health-care stocks this week. Not...
Keep Reading →
July 15 - News - Comments
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) has seen a decrease in hedge fund interest of late. According to most shareholders, hedge funds are seen as...
Keep Reading →
June 24 - News - Comments
Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) was in 11 hedge funds’ portfolio at the end of March. OPTR investors should be aware of a decrease in...
Keep Reading →
June 12 - News - Comments
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) investors should be aware of a decrease in enthusiasm from smart money lately. To most market participants,...
Keep Reading →
June 7 - News - Comments
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) shareholders have witnessed a decrease in activity from the world’s largest hedge funds lately. To the...
Keep Reading →
April 15 - News - Comments
Merrimack Pharmaceuticals Inc (NASDAQ:MACK) may be the perfect biotech company for your speculative portfolio. The company had its Initial Public Offering...
Keep Reading →
March 19 - News - Comments
It’s make-or-break time in 2013. That’s the situation for several biotech companies with critical phase 3 trials under way. Good results from...
Keep Reading →
February 13 - News - Comments
